Unichem Labs.

Why is Unichem Laboratories Ltd falling/rising?

As of 24-Aug, Unichem Laboratories Ltd's stock price is at Rs 509.40, down 3.12%, reflecting a trend reversal after two days of gains and decreased investor participation. The stock has underperformed its sector and is currently in a short-term bearish trend despite a positive year-to-date return.

As of 24-Aug, Unichem Laboratories Ltd's stock price is falling, currently at Rs 509.40, which reflects a decrease of Rs 16.4 or 3.12%. The stock has underperformed its sector by 3.09% today and has experienced a trend reversal, falling after two consecutive days of gains. The stock touched an intraday low of Rs 509, indicating a decline of 3.2% during the trading session. <BR><BR>Investor participation has also decreased, with delivery volume dropping by 22.53% compared to the 5-day average, suggesting reduced interest from investors. Although the stock is trading above its 100-day and 200-day moving averages, it is below the 5-day, 20-day, and 50-day moving averages, indicating a short-term bearish trend. <BR><BR>In the context of broader performance, the stock has seen a decline of 6.14% over the past week, contrasting with a slight drop of 0.46% in the Sensex. Despite a positive year-to-date return of 15.42%, the recent negative performance and falling investor participation contribute to the current decline in the stock price.

Which are the latest news on Unichem Labs.?

Who are in the management team of Unichem Labs.?

The management team of Unichem Labs includes Prafull Anubhai, Anand Mahajan, Prafull D Sheth, and Priti Puri as Independent Non-Executive Directors, Pranay Godha as a Non-Executive & Non-Independent Director, and Pabitra Bhattacharya as the Managing Director. They oversee the company's strategic direction and governance.

The management team of Unichem Labs includes the following members:<BR><BR>1. **Prafull Anubhai** - Independent Non-Executive Director<BR>2. **Anand Mahajan** - Independent Non-Executive Director<BR>3. **Prafull D Sheth** - Independent Non-Executive Director<BR>4. **Priti Puri** - Independent Non-Executive Director<BR>5. **Pranay Godha** - Non-Executive & Non-Independent Director<BR>6. **Pabitra Bhattacharya** - Managing Director<BR><BR>This team is responsible for overseeing the strategic direction and governance of the company.

What does Unichem Labs. do?

Unichem Laboratories Ltd is an Indian pharmaceutical company that manufactures active pharmaceutical ingredients, with a market cap of INR 3,848 Cr. As of June 2026, it reported net sales of 633 Cr and a net profit of 41 Cr.

Overview:<BR>Unichem Laboratories Ltd is an India-based pharmaceutical company that manufactures active pharmaceutical ingredients and operates in the Pharmaceuticals & Biotechnology industry within the small-cap market segment.<BR><BR>History:<BR>Unichem Laboratories Ltd was incorporated in an unspecified year and has maintained its status as a pharmaceutical manufacturer. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 633 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 41 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 3,848 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 31.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.08 <BR>Return on Equity: 2.58% <BR>Price to Book: 1.41 <BR><BR>Contact Details:<BR>Address: Unichem Bhavan Prabhat Estate, Off S V Road Jogeshwari (West) Mumbai Maharashtra : 400102 <BR>Tel: 91-22-66888333 <BR>Email: shares@unichemlabs.com <BR>Website: http://www.unichemlabs.com

Who are the peers of the Unichem Labs.?

Unichem Labs. peers include Morepen Labs., Gufic BioScience, Aarti Drugs, Novartis India, Guj. Themis Bio., SMS Pharma, Advanced Enzyme, Kwality Pharma, and Dishman Carbogen. Management risk varies from excellent at Novartis and Guj. Themis to below average at Dishman, with Unichem showing good growth and a 1-year return of 6.22%.

Peers: The peers of Unichem Labs. are Morepen Labs., Gufic BioScience, Aarti Drugs, Novartis India, Guj. Themis Bio., SMS Pharma., Advanced Enzyme, Kwality Pharma, Dishman Carbogen.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India and Guj. Themis Bio., while Average management risk is found at Morepen Labs., Gufic BioScience, Aarti Drugs, Unichem Labs., SMS Pharma., Advanced Enzyme, and Kwality Pharma, and the rest. Below Average management risk is noted at Dishman Carbogen. Growth is rated as Good for Novartis India, Unichem Labs., and Dishman Carbogen, while Below Average growth is seen at Morepen Labs., Gufic BioScience, Aarti Drugs, Guj. Themis Bio., SMS Pharma., Advanced Enzyme, and Kwality Pharma, and the rest. Capital Structure is Excellent for Morepen Labs., Novartis India, Guj. Themis Bio., and Advanced Enzyme, Good for Aarti Drugs and Unichem Labs., Average for Gufic BioScience and SMS Pharma, and Below Average for Dishman Carbogen.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kwality Pharma at 208.46%, while the lowest is Dishman Carbogen at -22.16%. Unichem Labs. has a 1-year return of 6.22%, which is significantly lower than Kwality Pharma's return but higher than Dishman Carbogen's. Additionally, Guj. Themis Bio., Advanced Enzyme, and Dishman Carbogen have negative six-month returns.

How big is Unichem Labs.?

As of 14th August, Unichem Laboratories Ltd has a market capitalization of 3,788.53 Cr, with net sales of 2,307.87 Cr and a net profit of 304.78 Cr reported in the latest four quarters. The company has shareholder's funds of 2,717.44 Cr and total assets of 3,706.88 Cr for the annual period ending in March 2026.

As of 14th August, Unichem Laboratories Ltd has a market capitalization of 3,788.53 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Unichem Laboratories reported net sales of 2,307.87 Cr and a net profit of 304.78 Cr.<BR><BR>For the latest annual period ending in March 2026, the company reported shareholder's funds of 2,717.44 Cr and total assets of 3,706.88 Cr.

Should I buy, sell or hold Unichem Laboratories Ltd?

Are Unichem Laboratories Ltd latest results good or bad?

Unichem Laboratories Ltd's latest results are concerning, showing a 2.05% decline in net sales and a 79.40% drop in net profit year-on-year, alongside a significant contraction in operating margins. The company's performance lags behind peers in the pharmaceutical sector, indicating deep-rooted operational challenges and a negative outlook.

Unichem Laboratories Ltd's latest results indicate significant challenges. In the fourth quarter of FY26, the company reported a net sales decline of 2.05% year-on-year, totaling ₹575.12 crores, despite a sequential recovery of 10.35% from the previous quarter. More concerning is the sharp contraction in operating margins, which fell to 8.29% from 14.25% a year ago, reflecting rising cost pressures and subdued demand.<BR><BR>The net profit for the quarter plummeted by 79.40% year-on-year to just ₹10.91 crores, and a staggering 95.87% decline compared to the previous quarter. This decline raises serious questions about the sustainability of earnings, especially since 75.35% of profit before tax was derived from other income, indicating a heavy reliance on non-operating income.<BR><BR>Overall, the results suggest that Unichem is facing deep-rooted operational challenges that extend beyond typical market fluctuations, leading to a negative outlook. The company's performance has significantly lagged behind its peers in the pharmaceutical sector, which reported an average return of 10.73% over the past year, while Unichem's stock has declined by 40.26% during the same period. Given these factors, the assessment of the latest results leans towards the negative side.

When is the next results date for Unichem Laboratories Ltd?

Unichem Laboratories Ltd will announce its results on 22 May 2026.

Unichem Laboratories Ltd is scheduled to declare its results on 22 May 2026.

Is Unichem Labs. technically bullish or bearish?

As of November 17, 2025, Unichem Labs shows a mildly bearish trend, with mixed signals from indicators like the MACD and Bollinger Bands, suggesting a cautious outlook for the stock.

As of 17 November 2025, the technical trend for Unichem Labs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands and KST both show a mildly bearish trend on both weekly and monthly time frames. Daily moving averages are bearish, and Dow Theory indicates no trend on the weekly but mildly bearish on the monthly. The overall lack of strong bullish signals, combined with the bearish indicators, suggests a cautious outlook for the stock.

Is Unichem Labs. overvalued or undervalued?

As of November 12, 2025, Unichem Labs. is considered attractive and undervalued compared to peers like Sun Pharma and Cipla, with a PE ratio of 22.88 and a strong 5-year return of 105.39%, despite recent stock performance lagging behind the Sensex.

As of 12 November 2025, the valuation grade for Unichem Labs. has moved from very attractive to attractive, indicating a shift in perception regarding its value. The company is currently assessed as undervalued, particularly in comparison to its peers. Key ratios include a PE ratio of 22.88, an EV to EBITDA of 14.21, and a PEG ratio of 0.05, which suggests strong growth potential relative to its price.<BR><BR>In the peer comparison, Unichem Labs. stands out against companies like Sun Pharma, which has a PE ratio of 35.94, and Cipla, with a PE ratio of 22.56. This positions Unichem Labs. favorably within the industry, especially considering its attractive valuation amidst peers that are deemed expensive. Despite recent stock performance lagging behind the Sensex over the past year, the long-term outlook remains positive, with a notable 5-year return of 105.39% compared to the Sensex's 94.82%.

How has been the historical performance of Unichem Labs.?

Unichem Labs has shown significant recovery and growth, with net sales increasing from 1,125.01 crore in March 2020 to 2,110.97 crore in March 2025, and a turnaround in profitability, achieving a profit after tax of 137.52 crore in March 2025 after previous losses. Despite rising total liabilities and negative cash flow from operating activities, the company has demonstrated resilience in its financial performance.

Answer:<BR>The historical performance of Unichem Labs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Unichem Labs has experienced a steady increase in net sales, rising from 1,125.01 crore in March 2020 to 2,110.97 crore in March 2025. This growth is reflected in total operating income, which also increased from 1,125.01 crore to 2,110.97 crore over the same period. The company's total expenditure, excluding depreciation, rose from 1,263.54 crore in March 2019 to 1,846.11 crore in March 2025, yet the operating profit (PBDIT) improved significantly, reaching 300.18 crore in March 2025, compared to a loss of 7.04 crore in March 2023. Profit before tax turned positive at 154.59 crore in March 2025, recovering from a loss of 176.36 crore in March 2023, while profit after tax also saw a turnaround, achieving 137.52 crore in March 2025 after losses in the previous two years. The company's total assets increased from 3,141.80 crore in March 2020 to 3,543.62 crore in March 2025, with total liabilities also rising from 3,141.80 crore to 3,543.62 crore. Cash flow from operating activities, however, remained negative at -7.00 crore in March 2025, despite a net cash outflow of -65.00 crore for the year. Overall, Unichem Labs has shown resilience and growth in its financial performance, particularly in sales and profitability metrics.

Who are the top shareholders of the Unichem Labs.?

The top shareholders of Unichem Labs include Ipca Laboratories Limited with 52.67%, mutual funds holding 9.89% (led by HDFC Small Cap Fund at 7.77%), and individual investors at 14.8%. Foreign Institutional Investors hold 0.98%, and there are no pledged promoter holdings.

The top shareholders of Unichem Labs include several key stakeholders. The majority shareholder is Ipca Laboratories Limited, which holds a significant 52.67% of the shares. Additionally, mutual funds collectively hold 9.89% through 7 different schemes, with HDFC Small Cap Fund being the highest public shareholder at 7.77%. Foreign Institutional Investors (FIIs) hold a smaller portion, with 0.98% across 40 FIIs. Individual investors account for 14.8% of the holdings. There are no pledged promoter holdings reported.

Has Unichem Labs. declared dividend?

Unichem Laboratories Ltd has declared a dividend of 200%, amounting to ₹4 per share, with an ex-date of August 1, 2022. Despite this, the dividend yield is 0%, and total returns over various periods show strong performance, particularly a 361.69% total return over the last 5 years.

Unichem Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: 01 Aug 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.5%, with a dividend return of 0%, resulting in a total return of -22.5%.<BR><BR>Over the past year, the price return was 13.02%, with a dividend return of 0%, leading to a total return of 13.02%.<BR><BR>In the 2-year period, the price return was 61.13%, with a dividend return of 0%, culminating in a total return of 61.13%.<BR><BR>For the 3-year period, the price return was 144.09%, with a dividend return of 1.72%, resulting in a total return of 145.81%.<BR><BR>In the 4-year period, the price return was 84.11%, with a dividend return of 1.25%, leading to a total return of 85.36%.<BR><BR>Over the last 5 years, the price return was 357.25%, with a dividend return of 4.44%, culminating in a total return of 361.69%.<BR><BR>Overall, Unichem Laboratories Ltd has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods show a mix of performance, with particularly strong returns over the longer term, especially in the 5-year period.